Recombinant allergens rarely allow identification of Hymenoptera venom–allergic patients with negative specific IgE to whole venom preparations - 01/08/14

| This study was funded in part by an unrestricted research grant of Thermo Fisher Scientific, Germany to T.J. (ZKF20120827). |
|
| Disclosure of potential conflict of interest: W. Pfutzner has received research support from the German Research Association and has received payment for lectures from ALK-Abelló and Novartis. E. Spillner is the cofounder of PLS-Design GmbH. F. Rueff is a member of the advisory board for ALK-Abelló, has consultant arrangements with DST GmbH, has received payment for lectures from Semperit Technische Produkte Gesellschaft mbH, ALK-Abelló Arzneimittel GmbH, Novartis Pharma, and Firma HAL; participated in clincial studies for Allergopharma, Bencard, HAL, Inventiv Health Clinical UK Ltd, and Novartis; and is an advisor for Bencard and ALK-Abelló. T. Jakob has received research support, consulting fees/honorarium, and travel support from Phadia/Thermo Fisher; has consultant arrangements with Allergopharma, Novartis, and Jansen Cilag; has received research support from Allergo Pharma, Thermo Fisher Scientific, Birken AG, and Cosmetic Europe; and has received payment for lectures from Stallergenes, ALK-Abelló, Allergies Therapeutics, and Novartis. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 134 - N° 2
P. 493 - août 2014 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
